The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Long-Acting Monoclonal Antibodies Market Research Report 2024
Synopsis
The global Long-Acting Monoclonal Antibodies market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Long-Acting Monoclonal Antibodies is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Long-Acting Monoclonal Antibodies is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Long-Acting Monoclonal Antibodies in Cancer is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Long-Acting Monoclonal Antibodies include Eli Lilly, Abbott Laboratories, AstraZeneca, Amgen, Bayer AG, Johnson & Johnson, Pfizer, GlaxoSmithKline and Merck, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Long-Acting Monoclonal Antibodies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Long-Acting Monoclonal Antibodies.
Report Scope
The Long-Acting Monoclonal Antibodies market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Long-Acting Monoclonal Antibodies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Long-Acting Monoclonal Antibodies companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Eli Lilly
Abbott Laboratories
AstraZeneca
Amgen
Bayer AG
Johnson & Johnson
Pfizer
GlaxoSmithKline
Merck
Novartis
Segment by Type
Murine Source
Chimeric Source
Human Source
Segment by Application
Cancer
Autoimmune Diseases
Inflammatory Diseases
Infectious Diseases
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Long-Acting Monoclonal Antibodies companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Long-Acting Monoclonal Antibodies market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Long-Acting Monoclonal Antibodies is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Long-Acting Monoclonal Antibodies is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Long-Acting Monoclonal Antibodies in Cancer is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Long-Acting Monoclonal Antibodies include Eli Lilly, Abbott Laboratories, AstraZeneca, Amgen, Bayer AG, Johnson & Johnson, Pfizer, GlaxoSmithKline and Merck, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Long-Acting Monoclonal Antibodies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Long-Acting Monoclonal Antibodies.
Report Scope
The Long-Acting Monoclonal Antibodies market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Long-Acting Monoclonal Antibodies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Long-Acting Monoclonal Antibodies companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Eli Lilly
Abbott Laboratories
AstraZeneca
Amgen
Bayer AG
Johnson & Johnson
Pfizer
GlaxoSmithKline
Merck
Novartis
Segment by Type
Murine Source
Chimeric Source
Human Source
Segment by Application
Cancer
Autoimmune Diseases
Inflammatory Diseases
Infectious Diseases
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Long-Acting Monoclonal Antibodies companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Long-Acting Monoclonal Antibodies Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Murine Source
1.2.3 Chimeric Source
1.2.4 Human Source
1.3 Market by Application
1.3.1 Global Long-Acting Monoclonal Antibodies Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Cancer
1.3.3 Autoimmune Diseases
1.3.4 Inflammatory Diseases
1.3.5 Infectious Diseases
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Long-Acting Monoclonal Antibodies Market Perspective (2019-2030)
2.2 Long-Acting Monoclonal Antibodies Growth Trends by Region
2.2.1 Global Long-Acting Monoclonal Antibodies Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Long-Acting Monoclonal Antibodies Historic Market Size by Region (2019-2024)
2.2.3 Long-Acting Monoclonal Antibodies Forecasted Market Size by Region (2025-2030)
2.3 Long-Acting Monoclonal Antibodies Market Dynamics
2.3.1 Long-Acting Monoclonal Antibodies Industry Trends
2.3.2 Long-Acting Monoclonal Antibodies Market Drivers
2.3.3 Long-Acting Monoclonal Antibodies Market Challenges
2.3.4 Long-Acting Monoclonal Antibodies Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Long-Acting Monoclonal Antibodies Players by Revenue
3.1.1 Global Top Long-Acting Monoclonal Antibodies Players by Revenue (2019-2024)
3.1.2 Global Long-Acting Monoclonal Antibodies Revenue Market Share by Players (2019-2024)
3.2 Global Long-Acting Monoclonal Antibodies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Long-Acting Monoclonal Antibodies Revenue
3.4 Global Long-Acting Monoclonal Antibodies Market Concentration Ratio
3.4.1 Global Long-Acting Monoclonal Antibodies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Long-Acting Monoclonal Antibodies Revenue in 2023
3.5 Long-Acting Monoclonal Antibodies Key Players Head office and Area Served
3.6 Key Players Long-Acting Monoclonal Antibodies Product Solution and Service
3.7 Date of Enter into Long-Acting Monoclonal Antibodies Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Long-Acting Monoclonal Antibodies Breakdown Data by Type
4.1 Global Long-Acting Monoclonal Antibodies Historic Market Size by Type (2019-2024)
4.2 Global Long-Acting Monoclonal Antibodies Forecasted Market Size by Type (2025-2030)
5 Long-Acting Monoclonal Antibodies Breakdown Data by Application
5.1 Global Long-Acting Monoclonal Antibodies Historic Market Size by Application (2019-2024)
5.2 Global Long-Acting Monoclonal Antibodies Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Long-Acting Monoclonal Antibodies Market Size (2019-2030)
6.2 North America Long-Acting Monoclonal Antibodies Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Long-Acting Monoclonal Antibodies Market Size by Country (2019-2024)
6.4 North America Long-Acting Monoclonal Antibodies Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Long-Acting Monoclonal Antibodies Market Size (2019-2030)
7.2 Europe Long-Acting Monoclonal Antibodies Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Long-Acting Monoclonal Antibodies Market Size by Country (2019-2024)
7.4 Europe Long-Acting Monoclonal Antibodies Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Long-Acting Monoclonal Antibodies Market Size (2019-2030)
8.2 Asia-Pacific Long-Acting Monoclonal Antibodies Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Long-Acting Monoclonal Antibodies Market Size by Region (2019-2024)
8.4 Asia-Pacific Long-Acting Monoclonal Antibodies Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Long-Acting Monoclonal Antibodies Market Size (2019-2030)
9.2 Latin America Long-Acting Monoclonal Antibodies Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Long-Acting Monoclonal Antibodies Market Size by Country (2019-2024)
9.4 Latin America Long-Acting Monoclonal Antibodies Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Long-Acting Monoclonal Antibodies Market Size (2019-2030)
10.2 Middle East & Africa Long-Acting Monoclonal Antibodies Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Long-Acting Monoclonal Antibodies Market Size by Country (2019-2024)
10.4 Middle East & Africa Long-Acting Monoclonal Antibodies Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Eli Lilly
11.1.1 Eli Lilly Company Detail
11.1.2 Eli Lilly Business Overview
11.1.3 Eli Lilly Long-Acting Monoclonal Antibodies Introduction
11.1.4 Eli Lilly Revenue in Long-Acting Monoclonal Antibodies Business (2019-2024)
11.1.5 Eli Lilly Recent Development
11.2 Abbott Laboratories
11.2.1 Abbott Laboratories Company Detail
11.2.2 Abbott Laboratories Business Overview
11.2.3 Abbott Laboratories Long-Acting Monoclonal Antibodies Introduction
11.2.4 Abbott Laboratories Revenue in Long-Acting Monoclonal Antibodies Business (2019-2024)
11.2.5 Abbott Laboratories Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Detail
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Long-Acting Monoclonal Antibodies Introduction
11.3.4 AstraZeneca Revenue in Long-Acting Monoclonal Antibodies Business (2019-2024)
11.3.5 AstraZeneca Recent Development
11.4 Amgen
11.4.1 Amgen Company Detail
11.4.2 Amgen Business Overview
11.4.3 Amgen Long-Acting Monoclonal Antibodies Introduction
11.4.4 Amgen Revenue in Long-Acting Monoclonal Antibodies Business (2019-2024)
11.4.5 Amgen Recent Development
11.5 Bayer AG
11.5.1 Bayer AG Company Detail
11.5.2 Bayer AG Business Overview
11.5.3 Bayer AG Long-Acting Monoclonal Antibodies Introduction
11.5.4 Bayer AG Revenue in Long-Acting Monoclonal Antibodies Business (2019-2024)
11.5.5 Bayer AG Recent Development
11.6 Johnson & Johnson
11.6.1 Johnson & Johnson Company Detail
11.6.2 Johnson & Johnson Business Overview
11.6.3 Johnson & Johnson Long-Acting Monoclonal Antibodies Introduction
11.6.4 Johnson & Johnson Revenue in Long-Acting Monoclonal Antibodies Business (2019-2024)
11.6.5 Johnson & Johnson Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Detail
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Long-Acting Monoclonal Antibodies Introduction
11.7.4 Pfizer Revenue in Long-Acting Monoclonal Antibodies Business (2019-2024)
11.7.5 Pfizer Recent Development
11.8 GlaxoSmithKline
11.8.1 GlaxoSmithKline Company Detail
11.8.2 GlaxoSmithKline Business Overview
11.8.3 GlaxoSmithKline Long-Acting Monoclonal Antibodies Introduction
11.8.4 GlaxoSmithKline Revenue in Long-Acting Monoclonal Antibodies Business (2019-2024)
11.8.5 GlaxoSmithKline Recent Development
11.9 Merck
11.9.1 Merck Company Detail
11.9.2 Merck Business Overview
11.9.3 Merck Long-Acting Monoclonal Antibodies Introduction
11.9.4 Merck Revenue in Long-Acting Monoclonal Antibodies Business (2019-2024)
11.9.5 Merck Recent Development
11.10 Novartis
11.10.1 Novartis Company Detail
11.10.2 Novartis Business Overview
11.10.3 Novartis Long-Acting Monoclonal Antibodies Introduction
11.10.4 Novartis Revenue in Long-Acting Monoclonal Antibodies Business (2019-2024)
11.10.5 Novartis Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Long-Acting Monoclonal Antibodies Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Murine Source
Table 3. Key Players of Chimeric Source
Table 4. Key Players of Human Source
Table 5. Global Long-Acting Monoclonal Antibodies Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Long-Acting Monoclonal Antibodies Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Long-Acting Monoclonal Antibodies Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Long-Acting Monoclonal Antibodies Market Share by Region (2019-2024)
Table 9. Global Long-Acting Monoclonal Antibodies Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Long-Acting Monoclonal Antibodies Market Share by Region (2025-2030)
Table 11. Long-Acting Monoclonal Antibodies Market Trends
Table 12. Long-Acting Monoclonal Antibodies Market Drivers
Table 13. Long-Acting Monoclonal Antibodies Market Challenges
Table 14. Long-Acting Monoclonal Antibodies Market Restraints
Table 15. Global Long-Acting Monoclonal Antibodies Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Long-Acting Monoclonal Antibodies Market Share by Players (2019-2024)
Table 17. Global Top Long-Acting Monoclonal Antibodies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-Acting Monoclonal Antibodies as of 2023)
Table 18. Ranking of Global Top Long-Acting Monoclonal Antibodies Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Long-Acting Monoclonal Antibodies Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Long-Acting Monoclonal Antibodies Product Solution and Service
Table 22. Date of Enter into Long-Acting Monoclonal Antibodies Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Long-Acting Monoclonal Antibodies Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Long-Acting Monoclonal Antibodies Revenue Market Share by Type (2019-2024)
Table 26. Global Long-Acting Monoclonal Antibodies Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Long-Acting Monoclonal Antibodies Revenue Market Share by Type (2025-2030)
Table 28. Global Long-Acting Monoclonal Antibodies Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Long-Acting Monoclonal Antibodies Revenue Market Share by Application (2019-2024)
Table 30. Global Long-Acting Monoclonal Antibodies Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Long-Acting Monoclonal Antibodies Revenue Market Share by Application (2025-2030)
Table 32. North America Long-Acting Monoclonal Antibodies Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Long-Acting Monoclonal Antibodies Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Long-Acting Monoclonal Antibodies Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Long-Acting Monoclonal Antibodies Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Long-Acting Monoclonal Antibodies Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Long-Acting Monoclonal Antibodies Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Long-Acting Monoclonal Antibodies Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Long-Acting Monoclonal Antibodies Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Long-Acting Monoclonal Antibodies Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Long-Acting Monoclonal Antibodies Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Long-Acting Monoclonal Antibodies Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Long-Acting Monoclonal Antibodies Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Long-Acting Monoclonal Antibodies Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Long-Acting Monoclonal Antibodies Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Long-Acting Monoclonal Antibodies Market Size by Country (2025-2030) & (US$ Million)
Table 47. Eli Lilly Company Detail
Table 48. Eli Lilly Business Overview
Table 49. Eli Lilly Long-Acting Monoclonal Antibodies Product
Table 50. Eli Lilly Revenue in Long-Acting Monoclonal Antibodies Business (2019-2024) & (US$ Million)
Table 51. Eli Lilly Recent Development
Table 52. Abbott Laboratories Company Detail
Table 53. Abbott Laboratories Business Overview
Table 54. Abbott Laboratories Long-Acting Monoclonal Antibodies Product
Table 55. Abbott Laboratories Revenue in Long-Acting Monoclonal Antibodies Business (2019-2024) & (US$ Million)
Table 56. Abbott Laboratories Recent Development
Table 57. AstraZeneca Company Detail
Table 58. AstraZeneca Business Overview
Table 59. AstraZeneca Long-Acting Monoclonal Antibodies Product
Table 60. AstraZeneca Revenue in Long-Acting Monoclonal Antibodies Business (2019-2024) & (US$ Million)
Table 61. AstraZeneca Recent Development
Table 62. Amgen Company Detail
Table 63. Amgen Business Overview
Table 64. Amgen Long-Acting Monoclonal Antibodies Product
Table 65. Amgen Revenue in Long-Acting Monoclonal Antibodies Business (2019-2024) & (US$ Million)
Table 66. Amgen Recent Development
Table 67. Bayer AG Company Detail
Table 68. Bayer AG Business Overview
Table 69. Bayer AG Long-Acting Monoclonal Antibodies Product
Table 70. Bayer AG Revenue in Long-Acting Monoclonal Antibodies Business (2019-2024) & (US$ Million)
Table 71. Bayer AG Recent Development
Table 72. Johnson & Johnson Company Detail
Table 73. Johnson & Johnson Business Overview
Table 74. Johnson & Johnson Long-Acting Monoclonal Antibodies Product
Table 75. Johnson & Johnson Revenue in Long-Acting Monoclonal Antibodies Business (2019-2024) & (US$ Million)
Table 76. Johnson & Johnson Recent Development
Table 77. Pfizer Company Detail
Table 78. Pfizer Business Overview
Table 79. Pfizer Long-Acting Monoclonal Antibodies Product
Table 80. Pfizer Revenue in Long-Acting Monoclonal Antibodies Business (2019-2024) & (US$ Million)
Table 81. Pfizer Recent Development
Table 82. GlaxoSmithKline Company Detail
Table 83. GlaxoSmithKline Business Overview
Table 84. GlaxoSmithKline Long-Acting Monoclonal Antibodies Product
Table 85. GlaxoSmithKline Revenue in Long-Acting Monoclonal Antibodies Business (2019-2024) & (US$ Million)
Table 86. GlaxoSmithKline Recent Development
Table 87. Merck Company Detail
Table 88. Merck Business Overview
Table 89. Merck Long-Acting Monoclonal Antibodies Product
Table 90. Merck Revenue in Long-Acting Monoclonal Antibodies Business (2019-2024) & (US$ Million)
Table 91. Merck Recent Development
Table 92. Novartis Company Detail
Table 93. Novartis Business Overview
Table 94. Novartis Long-Acting Monoclonal Antibodies Product
Table 95. Novartis Revenue in Long-Acting Monoclonal Antibodies Business (2019-2024) & (US$ Million)
Table 96. Novartis Recent Development
Table 97. Research Programs/Design for This Report
Table 98. Key Data Information from Secondary Sources
Table 99. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Long-Acting Monoclonal Antibodies Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Long-Acting Monoclonal Antibodies Market Share by Type: 2023 VS 2030
Figure 3. Murine Source Features
Figure 4. Chimeric Source Features
Figure 5. Human Source Features
Figure 6. Global Long-Acting Monoclonal Antibodies Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Long-Acting Monoclonal Antibodies Market Share by Application: 2023 VS 2030
Figure 8. Cancer Case Studies
Figure 9. Autoimmune Diseases Case Studies
Figure 10. Inflammatory Diseases Case Studies
Figure 11. Infectious Diseases Case Studies
Figure 12. Others Case Studies
Figure 13. Long-Acting Monoclonal Antibodies Report Years Considered
Figure 14. Global Long-Acting Monoclonal Antibodies Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 15. Global Long-Acting Monoclonal Antibodies Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global Long-Acting Monoclonal Antibodies Market Share by Region: 2023 VS 2030
Figure 17. Global Long-Acting Monoclonal Antibodies Market Share by Players in 2023
Figure 18. Global Top Long-Acting Monoclonal Antibodies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-Acting Monoclonal Antibodies as of 2023)
Figure 19. The Top 10 and 5 Players Market Share by Long-Acting Monoclonal Antibodies Revenue in 2023
Figure 20. North America Long-Acting Monoclonal Antibodies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. North America Long-Acting Monoclonal Antibodies Market Share by Country (2019-2030)
Figure 22. United States Long-Acting Monoclonal Antibodies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Canada Long-Acting Monoclonal Antibodies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Long-Acting Monoclonal Antibodies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Long-Acting Monoclonal Antibodies Market Share by Country (2019-2030)
Figure 26. Germany Long-Acting Monoclonal Antibodies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. France Long-Acting Monoclonal Antibodies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. U.K. Long-Acting Monoclonal Antibodies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Italy Long-Acting Monoclonal Antibodies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Russia Long-Acting Monoclonal Antibodies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Nordic Countries Long-Acting Monoclonal Antibodies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Long-Acting Monoclonal Antibodies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Long-Acting Monoclonal Antibodies Market Share by Region (2019-2030)
Figure 34. China Long-Acting Monoclonal Antibodies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Japan Long-Acting Monoclonal Antibodies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. South Korea Long-Acting Monoclonal Antibodies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Southeast Asia Long-Acting Monoclonal Antibodies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. India Long-Acting Monoclonal Antibodies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Australia Long-Acting Monoclonal Antibodies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Long-Acting Monoclonal Antibodies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Long-Acting Monoclonal Antibodies Market Share by Country (2019-2030)
Figure 42. Mexico Long-Acting Monoclonal Antibodies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Brazil Long-Acting Monoclonal Antibodies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Long-Acting Monoclonal Antibodies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Long-Acting Monoclonal Antibodies Market Share by Country (2019-2030)
Figure 46. Turkey Long-Acting Monoclonal Antibodies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Saudi Arabia Long-Acting Monoclonal Antibodies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Eli Lilly Revenue Growth Rate in Long-Acting Monoclonal Antibodies Business (2019-2024)
Figure 49. Abbott Laboratories Revenue Growth Rate in Long-Acting Monoclonal Antibodies Business (2019-2024)
Figure 50. AstraZeneca Revenue Growth Rate in Long-Acting Monoclonal Antibodies Business (2019-2024)
Figure 51. Amgen Revenue Growth Rate in Long-Acting Monoclonal Antibodies Business (2019-2024)
Figure 52. Bayer AG Revenue Growth Rate in Long-Acting Monoclonal Antibodies Business (2019-2024)
Figure 53. Johnson & Johnson Revenue Growth Rate in Long-Acting Monoclonal Antibodies Business (2019-2024)
Figure 54. Pfizer Revenue Growth Rate in Long-Acting Monoclonal Antibodies Business (2019-2024)
Figure 55. GlaxoSmithKline Revenue Growth Rate in Long-Acting Monoclonal Antibodies Business (2019-2024)
Figure 56. Merck Revenue Growth Rate in Long-Acting Monoclonal Antibodies Business (2019-2024)
Figure 57. Novartis Revenue Growth Rate in Long-Acting Monoclonal Antibodies Business (2019-2024)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
